Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV)

International Journal of Cancer

Volumn 118, Issue 6, 2006, Pages 1539-1544

  Zhu, Zhitong ^a   Jia, Jing ^a   Lu, Rong ^a,b   Lu, Yi ^a   Fu, Zheng ^a   Zhao, Lan ^a   Wang, Li ^a   Jin, Mengjue ^a   Zhao, Lin ^c   Gao, Wenyuan ^c   Yao, Zhi ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Shenzhen Kangzhe Pharmaceutical Co Ltd   (China)

^c TIANJIN UNIVERSITY   (China)

Author keywords

AKT; Antitumor; Nude mice; p21; p27; PI3k; PTEN; RT PCR; Tyroservatide, YSV; Western blot

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRIPEPTIDE; TYROSERVATIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN BEL 7402; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE AKT; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS TISSUE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644553799     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21501     Document Type: Article

References (37)

1. Dwyer JM. Transfer factor in the age of molecular biology: a review. Biotherapy 1996;9:7-11.
2. Berressem P. Application of glycopeptide fractions in the treatment of tumor patients suffering from immunodeficiency. Therapeutikon 1991;5:264-70.
3. Jing Jia, Rong Lu, Shuang Qiu, Huiqiang Li, Xuchun Che, Pengpeng Zhao, Mengjue Jin, Haixian Yang, Gang Lin, Zhi Yao. Preliminary investigation of the inhibitory effects of the tyroservatide (YSV) tripeptide on human hepatocarcinoma BEL-7402. Cancer Biol Ther 2005;9:e37-41, Epub ahead of print.
4. Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut 2005;54:109-16.
5. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8.
6. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998;22:152-6.
7. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA, Reed AL, Hilgers W, Kern SE, Koch WM, et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998;58:509-11.
8. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A, Viglielto G. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 2005;166:737-49.
9. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M, Lam EW. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000;275:21960-8.
10. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76.
11. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004;23:8571-80.
12. Han Y. Research and development of anticancer drugs and experimental techniques, 1st ed. Beijing, China: Peking University Health Center and Peking Union Medical College Publishing House, 1997. 299 p.
13. Chen Ruiming, Zhu Dehou, Ye Xiuzhen. The establishment and character of human hepacarcimoma cell line (BEL-7402) in vitro. Commun Sci 1975;20:434-6.
14. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-9.
15. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.
16. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, Haga T, Kikkawa U. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995;216:526-34.
17. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, Byreddy DV, Tavtigian SV, Bartel PL. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res 2000;60:35-7.
18. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001;276:48627-30.
19. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
20. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
21. Li YX, Huang PT. The application of polypeptides on biological medicine and diagnosis. J Chin Biol Chem 2001;22:193-4.
22. Chene P, Fuchs J, Bohn J, Garcia-Echeverria C, Furet P, Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol 2000;299:245-53.
23. Lei X, Han BL. The synthesis and effects on bile duct cancer in nude mice of Tuftsin. J Third Military Med Univ 2000;22:75-7.
24. Fazekas K, Raso E, Zarandi M, Dudas J, Timar J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 2002;22:2575-9.
25. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001;61:4985-9.
26. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-18.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
28. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 2000;60:7033-8.
29. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96:4240-5.
30. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000;1470:M21-35.
31. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 1997;94:3627-32.
32. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;25:210-29.
33. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995;17:471-80.
34. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44.
35. Cunningham JJ, Roussel MF. Cyclia-dependent kinase inhibitors in the development of the central nervous system. Cell Growth Differ 2001;12:387-96.
36. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.